Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
”Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease is a rare but clinically significant complement-mediated autoimmune hemolytic anemia driven by cold-reactive IgM antibodies.
What makes CAD particularly important is its dual presentation: chronic hemolysis alongside cold-induced circulatory symptoms such as acrocyanosis and Raynaud-like changes.
Diagnosis requires a high index of suspicion, with a characteristic C3d-positive direct antiglobulin test and evidence of complement activation.
Management has evolved significantly in recent years.
While cold avoidance and rituximab-based therapy remain important, targeted complement inhibition (e.g. sutimlimab) is transforming outcomes in selected patients.
Early recognition is key to preventing complications and improving quality of life.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 17:11Chokri Ben Lamine: Early Recognition and Immediate Treatment of Catastrophic APS
-
Aug 31, 2026, 17:06Nikolaos Ktenopoulos: COMPASS-ARTeCAT Trial Highlights Arterial Thrombosis in Patients With Cancer
-
Aug 31, 2026, 17:01Mark Kaplan: Same LDL-C, Different Coagulation, Different Outcomes, in FH
-
Aug 31, 2026, 16:55Kemal Karaagac: Milvexian Did Not Reduce Ischemic Events but Did Not Increase Fatal Bleeding
-
Aug 31, 2026, 16:47Improving Outcomes in AF-Related Stroke Beyond Anticoagulation at ESC 2026 – ESO
-
Aug 31, 2026, 16:39Shariq Shamim: Are We Going to Start DOAC post TAVI not DAPT?
-
Aug 31, 2026, 16:30Bartosz Hudzik: 5th Universal MI Definition Moves Closer to Biology in Women
-
Aug 31, 2026, 16:13Seema Dawood: Nucleated Red Blood Cells – What They Tell Us on a Peripheral Smear
-
Aug 31, 2026, 16:02Antonio Sorropago: Major Updates in Structural Heart Interventions